Craig A Beam1, Colleen MacCallum2, Kevan C Herold3, Diane K Wherrett4, Jerry Palmer5, Johnny Ludvigsson6. 1. Division of Epidemiology and Biostatistics, Department of Biomedical Sciences, Western Michigan University Homer Stryker M.D. School of Medicine, 1000 Oakland Drive, Kalamazoo, MI, 49008-8071, USA. craig.beam@med.wmich.edu. 2. Division of Epidemiology and Biostatistics, Department of Biomedical Sciences, Western Michigan University Homer Stryker M.D. School of Medicine, 1000 Oakland Drive, Kalamazoo, MI, 49008-8071, USA. 3. Departments of Immunobiology and Internal Medicine, Yale University, New Haven, CT, USA. 4. Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada. 5. University of Washington and VA Puget Sound Health Care System, Seattle, WA, USA. 6. Divison of Pediatrics, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Abstract
AIMS/HYPOTHESIS: GAD is a major target of the autoimmune response that occurs in type 1 diabetes mellitus. Randomised controlled clinical trials of a GAD + alum vaccine in human participants have so far given conflicting results. METHODS: In this study, we sought to see whether a clearer answer to the question of whether GAD65 has an effect on C-peptide could be reached by combining individual-level data from the randomised controlled trials using Bayesian meta-analysis to estimate the probability of a positive biological effect (a reduction in C-peptide loss compared with placebo approximately 1 year after the GAD vaccine). RESULTS: We estimate that there is a 98% probability that 20 μg GAD with alum administered twice yields a positive biological effect. The effect is probably a 15-20% reduction in the loss of C-peptide at approximately 1 year after treatment. This translates to an annual expected loss of between -0.250 and -0.235 pmol/ml in treated patients compared with an expected 2 h AUC loss of -0.294 pmol/ml at 1 year for untreated newly diagnosed patients. CONCLUSIONS/ INTERPRETATION: The biological effect of this vaccination should be developed further in order to reach clinically desirable reductions in insulin loss in patients recently diagnosed with type 1 diabetes.
AIMS/HYPOTHESIS: GAD is a major target of the autoimmune response that occurs in type 1 diabetes mellitus. Randomised controlled clinical trials of a GAD + alum vaccine in humanparticipants have so far given conflicting results. METHODS: In this study, we sought to see whether a clearer answer to the question of whether GAD65 has an effect on C-peptide could be reached by combining individual-level data from the randomised controlled trials using Bayesian meta-analysis to estimate the probability of a positive biological effect (a reduction in C-peptide loss compared with placebo approximately 1 year after the GAD vaccine). RESULTS: We estimate that there is a 98% probability that 20 μg GAD with alum administered twice yields a positive biological effect. The effect is probably a 15-20% reduction in the loss of C-peptide at approximately 1 year after treatment. This translates to an annual expected loss of between -0.250 and -0.235 pmol/ml in treated patients compared with an expected 2 h AUC loss of -0.294 pmol/ml at 1 year for untreated newly diagnosed patients. CONCLUSIONS/ INTERPRETATION: The biological effect of this vaccination should be developed further in order to reach clinically desirable reductions in insulin loss in patients recently diagnosed with type 1 diabetes.
Authors: W M Kuhtreiber; S L L Washer; E Hsu; M Zhao; P Reinhold; D Burger; H Zheng; D L Faustman Journal: Diabet Med Date: 2015-08-16 Impact factor: 4.359
Authors: Zachary Skrivanek; Scott Berry; Don Berry; Jenny Chien; Mary Jane Geiger; James H Anderson; Brenda Gaydos Journal: J Diabetes Sci Technol Date: 2012-11-01
Authors: Johnny Ludvigsson; David Krisky; Rosaura Casas; Tadej Battelino; Luis Castaño; James Greening; Olga Kordonouri; Timo Otonkoski; Paolo Pozzilli; Jean-Jacques Robert; Henk J Veeze; Jerry Palmer; Ulf Samuelsson; Helena Elding Larsson; Jan Åman; Gunilla Kärdell; Jan Neiderud Helsingborg; Göran Lundström; Eva Albinsson; Annelie Carlsson; Maria Nordvall; Hans Fors; Carl-Göran Arvidsson; Stig Edvardson; Ragnar Hanås; Karin Larsson; Björn Rathsman; Henrik Forsgren; Helena Desaix; Gun Forsander; Nils-Östen Nilsson; Carl-Göran Åkesson; Päivi Keskinen; Riitta Veijola; Timo Talvitie; Klemens Raile; Thomas Kapellen; Walter Burger; Andreas Neu; Ilse Engelsberger; Bettina Heidtmann; Suzanne Bechtold; David Leslie; Francesco Chiarelli; Alesandro Cicognani; Giuseppe Chiumello; Franco Cerutti; Gian Vincenzo Zuccotti; Ana Gomez Gila; Itxaso Rica; Raquel Barrio; Maria Clemente; Maria José López Garcia; Mercedes Rodriguez; Isabel Gonzalez; Juan Pedro Lopez; Mirentxu Oyarzabal; H M Reeser; Roos Nuboer; Pauline Stouthart; Natasa Bratina; Nina Bratanic; Marc de Kerdanet; Jacques Weill; Nicole Ser; Pascal Barat; Anne Marie Bertrand; Jean-Claude Carel; Rachel Reynaud; Regis Coutant; Sabine Baron Journal: N Engl J Med Date: 2012-02-02 Impact factor: 91.245
Authors: J Tian; M Clare-Salzler; A Herschenfeld; B Middleton; D Newman; R Mueller; S Arita; C Evans; M A Atkinson; Y Mullen; N Sarvetnick; A J Tobin; P V Lehmann; D L Kaufman Journal: Nat Med Date: 1996-12 Impact factor: 53.440
Authors: Mark A Atkinson; Bart O Roep; Amanda Posgai; Daniel C S Wheeler; Mark Peakman Journal: Lancet Diabetes Endocrinol Date: 2018-10-24 Impact factor: 32.069
Authors: Johnny Ludvigsson; Indusmita Routray; Sriramulu Elluru; Per Leanderson; Helena E Larsson; Björn Rathsman; Ragnar Hanås; Annelie Carlsson; Torben Ek; Ulf Samuelsson; Torun Torbjörnsdotter; Jan Åman; Eva Örtqvist; Karun Badwal; Craig Beam; Rosaura Casas Journal: Future Sci OA Date: 2020-06-23